4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes
clinical trial
Press Enter · cited answer in seconds
0 sources
Summary
4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes is a clinical trial[1].
Key Facts
- 4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes is in the country of United States[2].
- 4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes's instance of is recorded as clinical trial[3].
- 4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes's start time is recorded as +2018-06-25T00:00:00Z[4].
- 4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes's end time is recorded as +2019-06-17T00:00:00Z[5].
- 4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes's sponsor is recorded as Pfizer[6].
- 4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes's main subject is recorded as diabetes[7].
- 4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes's number of participants is recorded as {'unit': '1', 'amount': '+96'}[8].
- 4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes's title is recorded as A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE ESCALATING ORAL DOSES OF PF-06882961 IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS[9].
- 4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes's uses is recorded as partial thromboplastin time[10].
- 4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[11].
- 4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes's ClinicalTrials.gov ID is recorded as NCT03538743[12].
- 4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+70'}[13].
- 4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes's clinical trial phase is recorded as phase I clinical trial[14].
- 4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes's research subject recruitment status is recorded as completed[15].
- 4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes's study type is recorded as interventional study[16].